Items where Author is "Dippel, E."

Article

Schadendorf, D. and Hassel, J. C. and Fluck, M. and Eigentler, T. and Loquai, C. and Haferkamp, S. and Gutzmer, R. and Meier, F. and Mohr, P. and Hauschild, A. and Menzer, C. and Kiecker, F. and Dippel, E. and Simon, J-C. and Conrad, B. and Garbe, C. and Körner, S. and Becker, J. C. and Zimmer, L. and Livingstone, E. (2022) Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial. ANNALS OF ONCOLOGY, 33 (Suppl7). S900. ISSN 0923-7534, 1569-8041

Livingstone, E. and Eigentler, T. K. and Windemuth-Kieselbach, C. and Hauschild, A. and Rompel, R. and Trefzer, U. and Nashan, D. and Kilian, K. and Debus, D. and Kähler, K. C. and Mauerer, A. and Möllenhoff, K. and Dippel, E. and Schadendorf, D. (2015) Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study. BRITISH JOURNAL OF DERMATOLOGY, 172 (6). pp. 1646-1650. ISSN 0007-0963, 1365-2133

Conference or Workshop Item

Franklin, C. and Mohr, P. and Meier, F. and Weichenthal, M. and Grimmel-Mann, I. and Gutzmer, R. and Utikal, J. S. and Terheyden, P. and Herbst, R. and Haferkamp, Sebastian and Pföhler, C. and Leiter-Stöppke, U. and Ziller, F. and Meiß, F. and Ulrich, J. and Kreuter, A. and Gebhardt, C. and Welzel, J. and Schilling, B. and Kaatz, M. and Scharfetter-Kochanek, K. and Dippel, E. and Nashan, D. and Sachse, M. M. and Weishaupt, C. and Löffler, H. and Gambichler, T. and Loquai, C. and Heinzerling, L. and Grabbe, S. and Debus, D. and Schley, G. and Weyandt, G. and Trommer, M. and Lodde, G. and Placke, J. M. and Zimmer, L. and Livingstone, E. and Horn, S. and Schadendorf, D. and Ugurel, S. (2022) FV20 Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Franklin, C. and Mohr, P. and Bluhm, L. and Grimmelmann, I. and Gutzmer, R. and Meier, F. and Garzarolli, M. and Weichenthal, M. and Herbst, R. and Pföhler, C. and Terheyden, P. and Utikal, J. S. and Ulrich, J. and Debus, D. and Haferkamp, Sebastian and Kaatz, M. and Forschner, A. and Leiter-Stöppke, U. and Nashan, D. and Kreuter, A. and Sachse, M. M. and Welzel, J. and Heinzerling, L. and Meiß, F. and Weishaupt, C. and Gambichler, T. and Weyandt, G. and Dippel, E. and Schatton, K. and Celik, E. and Trommer, M. and Helfrich, I. and Rösch, A. and Zimmer, L. and Livingstone, E. and Schaden-Dorf, D. and Horn, S. and Ugurel, S. (2022) eP003 Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Other

Schadendorf, D. and Hassel, J. C. and Fluck, M. and Eigentler, T. and Loquai, C. and Berneburg, M. and Gutzmer, R. and Meier, F. and Mohr, P. and Hauschild, A. and Becker, J. C. and Menzer, C. and Kiecker, F. and Dippel, E. and Simon, J-C. and Conrad, B. and Garbe, C. and Koerner, S. and Livingstone, E. and Zimmer, L. (2019) Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). OXFORD UNIV PRESS, OXFORD.

Livingstone, E. and Eigentler, T. and Rompel, R. and Meiss, F. and Mauerer, A. and Kaehler, K. and Dippel, E. and Moellenhoff, K. and Kilian, K. and Kretschmer, L. and Debus, D. and Windemuth-Kieselbach, C. and Hauschild, A. and Schadendorf, D. (2013) Quality Assurance Project Melanoma: Results of the final Survey 4 Years after initial Diagnosis. WILEY-BLACKWELL, HOBOKEN.